Robert Cascella Purchases 100,000 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) Director Robert Cascella acquired 100,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was acquired at an average price of $0.75 per share, for a total transaction of $75,000.00. Following the purchase, the director now directly owns 453,098 shares in the company, valued at $339,823.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Robert Cascella also recently made the following trade(s):

• On Monday, August 19th, Robert Cascella purchased 4,000 shares of Neuronetics stock. The stock was acquired at an average price of $1.14 per share, for a total transaction of $4,560.00.
• On Friday, August 16th, Robert Cascella acquired 35,000 shares of Neuronetics stock. The shares were bought at an average cost of $1.06 per share, for a total transaction of $37,100.00.
• On Wednesday, August 14th, Robert Cascella bought 35,000 shares of Neuronetics stock. The stock was purchased at an average cost of $0.79 per share, with a total value of $27,650.00.

Neuronetics Stock Down 1.2 %

NASDAQ STIM opened at $0.73 on Friday. The stock has a 50 day moving average price of $1.37 and a 200-day moving average price of $2.49. Neuronetics, Inc. has a one year low of $0.66 and a one year high of $5.07. The company has a debt-to-equity ratio of 2.38, a quick ratio of 2.37 and a current ratio of 2.58. The company has a market capitalization of $22.15 million, a P/E ratio of -0.76 and a beta of 2.27.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. The business had revenue of $16.45 million for the quarter, compared to the consensus estimate of $18.76 million. During the same quarter last year, the business earned ($0.17) EPS. As a group, equities analysts predict that Neuronetics, Inc. will post -0.87 EPS for the current fiscal year.

Analyst Ratings Changes

STIM has been the topic of several recent analyst reports. JMP Securities reduced their price objective on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. William Blair reiterated a “market perform” rating on shares of Neuronetics in a research note on Monday, August 12th. Finally, Canaccord Genuity Group cut their price objective on Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. First Washington CORP raised its position in Neuronetics by 88.8% during the second quarter. First Washington CORP now owns 1,274,540 shares of the company’s stock valued at $2,294,000 after purchasing an additional 599,455 shares during the period. Silvercrest Asset Management Group LLC raised its stake in shares of Neuronetics by 4.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 1,178,365 shares of the company’s stock valued at $5,609,000 after acquiring an additional 51,881 shares during the period. First Eagle Investment Management LLC raised its stake in shares of Neuronetics by 33.4% in the second quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock valued at $1,870,000 after acquiring an additional 260,000 shares during the period. Millrace Asset Group Inc. lifted its holdings in shares of Neuronetics by 205.1% in the 4th quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company’s stock worth $2,104,000 after acquiring an additional 487,591 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Neuronetics by 23.7% during the 2nd quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock worth $587,000 after purchasing an additional 62,628 shares during the period. Institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.